Nano Holdings, Inc. (FRA:3NQ)

Market Cap	71.83M +14.4%
Revenue (ttm)	841.99K +36.0%
Net Income	-4.82M
EPS	-0.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	75
Average Volume	4
Open	0.9250
Previous Close	0.9550
Day's Range	0.9250 - 0.9250
52-Week Range	0.6600 - 1.1500
Beta	n/a
RSI	71.69
Earnings Date	Feb 13, 2026

About Nano Holdings

Nano Holdings, Inc. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. The company’s pipeline products include RUNX1 (mRNA) for the treatment knee osteoarthritis and reduces pain; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma multiforme. In addition, it offers cosmetic raw material. The company was formerly known as NANO MRNA Co.,Ltd. and changed its name to Nano Holdings,...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1996
• Employees: 20
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 3NQ

Financial Performance

In fiscal year 2025, Nano Holdings's revenue was 108.00 million, a decrease of -20.00% compared to the previous year's 135.00 million. Losses were -835.00 million, 7.05% more than in 2024.

Financial numbers in JPY